NCT05675410 2026-04-22
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06952803 2026-04-21
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT06124157 2026-04-20
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06890884 2026-04-20
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06925737 2026-04-20
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04884035 2026-04-17
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Celgene
Phase 1 Recruiting
NCT06317662 2026-04-16
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07005154 2026-04-02
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT03959085 2026-03-31
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting